GamEvac-Combi

GamEvac-Combi

GamEvac-Combi

Heterologous VSV- and Ad5-vectored Ebola vaccine


GamEvac-Combi (Russian: ГамЭвак-Комби) is a heterologous VSV- and Ad5-vectored Ebola vaccine. There is also a version called GamEvac which is a homologous Ad5-vectored vaccine.[1] GamEvac-Combi was developed by Gamaleya Research Institute of Epidemiology and Microbiology. As of 2015 the vaccine has been licensed in Russia for emergency use, on the basis of Phase 1 and Phase 2 clinical trials.[2]

Quick Facts Vaccine description, Target ...

Description

The vaccine consists of live-attenuated recombinant vesicular stomatitis virus (VSV) and adenovirus serotype-5 (Ad5) expressing Ebola envelope glycoprotein.[3] The vaccine is targeted against the Makona variant of Ebola that was circulating in West Africa during the 2013-2016 outbreak.[4]

History

GamEvac-Combi was licensed by the Ministry of Health of the Russian Federation for emergency use in the territory of the Russian Federation in December 2015. The emergency license was based on Phase I and II clinical data of safety and immunogenicity.[2]

See also


References

  1. Dolzhikova IV, Tokarskaya EA, Dzharullaeva AS, Tukhvatulin AI, Shcheblyakov DV, Voronina OL, et al. (2017). "Virus-Vectored Ebola Vaccines". Acta Naturae. 9 (3): 4–11. doi:10.32607/20758251-2017-9-3-4-11. PMC 5662269. PMID 29104771.
  2. Dolzhikova IV, Zubkova OV, Tukhvatulin AI, Dzharullaeva AS, Tukhvatulina NM, Shcheblyakov DV, et al. (March 2017). "Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia". Human Vaccines & Immunotherapeutics. 13 (3): 613–620. doi:10.1080/21645515.2016.1238535. PMC 5360131. PMID 28152326.
  3. Malvy D, McElroy AK, de Clerck H, Günther S, van Griensven J (March 2019). "Ebola virus disease". Lancet. 393 (10174): 936–948. doi:10.1016/s0140-6736(18)33132-5. PMID 30777297.

Share this article:

This article uses material from the Wikipedia article GamEvac-Combi, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.